On Monday, BridgeBio Pharma Inc (NASDAQ: BBIO) opened higher 2.63% from the last session, before settling in for the closing price of $46.47. Price fluctuations for BBIO have ranged from $21.72 to $46.80 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -3.04% annually for the last half of the decade. Company’s average yearly earnings per share was noted 1.42% at the time writing. With a float of $160.86 million, this company’s outstanding shares have now reached $189.83 million.
In an organization with 730 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 96.95%, operating margin of -547.57%, and the pretax margin is -528.55%.
BridgeBio Pharma Inc (BBIO) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of BridgeBio Pharma Inc is 15.28%, while institutional ownership is 83.47%. The most recent insider transaction that took place on Jul 02 ’25, was worth 1,709,050. In this transaction Chief Executive Officer of this company sold 40,000 shares at a rate of $42.73, taking the stock ownership to the 955,686 shares. Before that another transaction happened on Jul 01 ’25, when Company’s Chief Executive Officer sold 40,000 for $42.54, making the entire transaction worth $1,701,400. This insider now owns 975,686 shares in total.
BridgeBio Pharma Inc (BBIO) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 1.42% per share during the next fiscal year.
BridgeBio Pharma Inc (NASDAQ: BBIO) Trading Performance Indicators
Check out the current performance indicators for BridgeBio Pharma Inc (BBIO). In the past quarter, the stock posted a quick ratio of 4.54. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 71.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.53, a number that is poised to hit -0.74 in the next quarter and is forecasted to reach -1.63 in one year’s time.
Technical Analysis of BridgeBio Pharma Inc (BBIO)
Let’s dig in a bit further. During the last 5-days, its volume was 3.02 million. That was inferior than the volume of 3.08 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 89.47%.
During the past 100 days, BridgeBio Pharma Inc’s (BBIO) raw stochastic average was set at 95.13%, which indicates a significant increase from 85.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.51 in the past 14 days, which was lower than the 1.62 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $38.84, while its 200-day Moving Average is $32.30. However, in the short run, BridgeBio Pharma Inc’s stock first resistance to watch stands at $48.65. Second resistance stands at $49.61. The third major resistance level sits at $50.53. If the price goes on to break the first support level at $46.76, it is likely to go to the next support level at $45.84. The third support level lies at $44.88 if the price breaches the second support level.
BridgeBio Pharma Inc (NASDAQ: BBIO) Key Stats
There are currently 189,881K shares outstanding in the company with a market cap of 9.06 billion. Presently, the company’s annual sales total 221,900 K according to its annual income of -535,760 K. Last quarter, the company’s sales amounted to 116,630 K and its income totaled -167,420 K.
